A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy

Trial Profile

A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs Venetoclax (Primary) ; Azacitidine; Decitabine; Posaconazole
  • Indications Acute myeloid leukaemia
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 12 Jul 2018 According to a Roche media release, based on the data of this study, the company has submitted New Drug Application (sNDA) to the United States (U.S.) Food and Drug Administration (FDA) for Venclexta.
    • 17 Jun 2018 Preliminary results (Data cut-off: July 7, 2017; n=145) presented at the 23rd Congress of the European Haematology Association
    • 05 Jun 2018 Preliminary results (data cut off: 7 Jul, 2017; n=145)presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top